Cargando…
Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy
Rationally designed multi-target drugs (also termed multimodal drugs, network therapeutics, or designed multiple ligands) have emerged as an attractive drug discovery paradigm in the last 10–20 years, as potential therapeutic solutions for diseases of complex etiology and diseases with significant d...
Autor principal: | Löscher, Wolfgang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580162/ https://www.ncbi.nlm.nih.gov/pubmed/34776956 http://dx.doi.org/10.3389/fphar.2021.730257 |
Ejemplares similares
-
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
por: Ni, Xiayun, et al.
Publicado: (2022) -
Target-specific compound selectivity for multi-target drug discovery and repurposing
por: Wang, Tianduanyi, et al.
Publicado: (2022) -
The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy
por: Alves, Mariana, et al.
Publicado: (2018) -
Drugs and Targets in Fibrosis
por: Li, Xiaoyi, et al.
Publicado: (2017) -
Editorial: Drug repurposing and polypharmacology: A synergistic approach in multi-target based drug discovery
por: Rudrapal, Mithun, et al.
Publicado: (2022)